Teva faces $2 billion damages for selling generic Protonix


Israeli company Teva Pharmaceuticals could be forced to pay more than $2 billion in damages for selling a generic version of Nycomed and Pfizer’s heartburn reliever Protonix before the drug’s patent exclusivity expired in the US.

Teva, Pfizer, Nycomed, Protonix, generics, damages